Cancers, Rago (Novartis): "Turn to Improve Quality of Life Patients with Lmc"
10 Articles
10 Articles
We have created a very simple digital tool, called Vita Lmc Tracker, which serves patients to monitor the signs and symptoms of the disease and bring this information into the study of their doctor, so that they can have a more informed medical-patient discussion. Marco Rago, Medical Head Oncology Novartis Italia, told us, at the meeting with the press, promoted by the pharmaceutical in Milan on chronic myeloid leukaemia, live with, listen to, p…
(Adnkronos) "The therapeutic innovation has allowed to change the history" of chronic myeloid leukemia (Lmc) "and to achieve a very high survival. Alongside the scientific component of research and development, Novartis, engaged for about 30 years in oncoematology, in particular in the Lmc, wants to deal with listening to the needs of patients, especially as regards [...]
(Adnkronos) therapeutic innovation has made it possible to change the history of chronic myeloid leukaemia (Lmc) and to achieve a very high survival. Alongside the scientific component of research and development, Novartis, engaged for about 30 years in oncoematology, in particular in the Lmc, wants to deal with listening to the needs of patients, especially as regards the [...] L'articolo Tumori, Rago (Novartis): "Impegnati a migliori qualità v…
(Adnkronos) - Today we have therapies for the treatment of chronic myeloid leukaemia (Lmc) that seem to be very well tolerated and,
Rome, 16 Sep. (AdnKronos Salute) - "The therapeutic innovation has allowed to change the history" of chronic myeloid leukemia (Lmc) "and to achieve a very high survival. Alongside the scientific component of research and development, Novartis, engaged for about 30 years in oncoematology, in particular in the context of Lmc, wants to deal with the listening of the needs of patients, especially as regards their quality of life. Marco Rago, Medical…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium






